Visit their website here https://www.genscript.com/
GenScript Biotech Corporation is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
hermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
Honeywell Process Solutions is a pioneer in automation control, instrumentation and services for the oil and gas; refining; energy; pulp and paper; industrial power generation; chemicals and petrochemicals; biofuels; life sciences; and metals, minerals and mining industries. It is also a leader in providing software solutions and instrumentation that help manufacturers find value and competitive advantage in through Honeywell Connected Plant, Honeywell’s Industrial Internet of Things (IIoT) solution. To learn more about Honeywell Life Sciences automation, visit: www.honeywellprocess.com/batch
Kajima Corporation commenced operations in 1840. During this history of about 180 years, Kajima has improved people’s lives by ensuring safety, security and a more rewarding life. We have created numerous social infrastructures including advanced structures, transportation networks, energy facilities and urban complexes. In addition to civil and building construction areas described above, Kajima also provides process engineering services to clients. Numerous EPC and EP/CM projects have been completed, mainly involving facilities for the pharmaceutical, cosmetics and food industries. In Asia, The Company has subsidiary companies in Singapore, Malaysia, Thailand, Vietnam, Philippines, Indonesia, and Myanmar.
Merck, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. Our comprehensive portfolio supports customers during all stages of the drug manufacturing process. With our broad range of products, applications and services including single-use manufacturing, filtration, chromatography and purification, virus reduction, pharma and biopharma raw materials, drug delivery compounds, and engineering and validation services we are committed to best support your goals of intensified, connected or continuous bioprocessing. Our industry expertise and regulatory know-how help you get to clinic faster, allowing you to focus on what matters most — delivering safe, effective therapies sooner to the patients that need them most.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000- strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speedup time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.
About United Biopharma: http://ubp-cdmo.com/
United BioPharma (UBP) is a professional contract development and manufacturing organization (CDMO) that provides highly integrated and customizable services in biopharmaceutical development and cGMP manufacturing.
UBP has a long history of discovery, research and development of biologics such as highly potent monoclonal antibodies for HIV, autoimmune diseases, and cancer. We have built a broad range of cutting-edge capabilities and facilities located in multiple countries provide cell line development, process development, analytical method development and GMP manufacturing services for our clients.
Our goal is to work as your partner at each stage of the development of your products. We are committed to providing quality-driven contract services for the development and manufacturing of biologics with our integrated capabilities.
UBP is your reliable partner with strong technical expertise in the development and GMP manufacturing of biologics to help you deliver innovative and life-changing therapeutics to patients.
Jianshun Biosciences Co., Ltd. (“JS Bio”) founded in March 2011, JS Bio is committed to the development, production and sale of high-quality, high-efficiency serum-free, commercialized, chemically defined cell culture media products. At the same time, it provides formula production, process optimization, technical support and other ancillary services for those bio-pharmaceutical industry and human and veterinary vaccine enterprises. JS Bio has passed ISO9000 quality management system, ISO14000 environment management system and ISO13485 medical device quality management system certification. JS Bio has a world-class R&D team and world-class biosafety laboratories in Lanzhou and Shanghai Zhangjiang respectively. Currently, JS Bio has an annual production capacity of 300 tons of cell culture medium in Lanzhou.
JS Bio (Haimen) is the second-phase plant of JSBio. It has started construction since Jan 1, 2019. The plant will adopt the latest design concept and fully comply with international GMP requirements. It is expected to be completed and put into production in the second half of 2019 and will become the largest powder cell culture medium producer in the world.
USP is an independent non-profit organization that collaborates with the world’s top health and science experts to develop high-quality standards that set the bar for manufacturing and distributing safe and effective medicines, supplements and food around the globe. Two billion people world-wide have access to quality medicines, dietary supplements and food as a result of USP’s standards, advocacy and education.
At USP Biologics our primary objective is to keep you at the vanguard of standards that promote the quality of biological medicines. We do this through our rigorous and proven scientific process. And we place the outcome of our process – the physical standard as well as the method or supporting information– into your hands.
We provide a trusted, independent, single source of reliable standards that are available and used globally. Building upon our successes with more traditional biologics including Insulin and Heparin, we engage with thousands of experts, professionals, associations, regulatory agencies, and companies to pave the way for higher standards for the new wave of biologics and biosimilar drugs. It’s logical really: by actively working with the scientific community and making our rigorously researched standards available to the world, we enable you to provide access to quality medicines for all. Through a collaborative process and commitment to quality, our USP’s biologic standards help by delivering key tools and resources to help make critical medicines, such as the insulin family of products, more accessible to the global population.
To assist you in achieving high standards in drug validation and regulatory compliance as well as avoiding potentially costly mistakes, choose our globally renowned scientific approach that has provided trustworthy standards for decades. Logical really. Our process is as robust as the results you will achieve.
So why not talk with us and find out how we can help advance your biologics and biosimilars project with reliable standards?
XiKang (WuHan) Biopharmaceutical Co., Ltd
Pneumatic Scale Angelus is a manufacturer of continuous flow centrifuges for the biotech industry. The brands Centritech and CARR are well known in the industry for many years. Our main focus during the last years has been in the single-use centrifuges, offering the Centritech Lab III and CELL 8 for perfusion cell cultures at any scale and the UniFuge® Single-use Separation System for vaccine, stem cell and monoclonal antibody manufacturing. PSA now offers the U2k® Single-use Separation System for cell culture harvesting up to 2000 liters.
Pneumatic Scale Angelus is also the manufacturer of the CARR Powerfuge® and ViaFuge®. Both machines are industrial stainless steel continuous flow centrifuges, available in various sizes. While the ViaFuge® is used for mammalian cell separation, the Powerfuge® is our high G model for solid liquid separation.
Our business is influenced by the growth in demand for biologic drugs, particularly the global market for monoclonal antibodies (mAbs). Demand for our products is associated with the overall volume of mAbs manufactured; there is little connection to final drug pricing or the clinical or commercial success or failure of an individual biologic drug.
As the number of biologic drugs on the market and in development continues to increase, and as worldwide access to biologics expands with the emergence of biosimilar and bio-better versions of original drugs, biopharmaceutical manufacturers are tasked with reducing the time and cost associated with production while improving yield and retaining the highest levels of product quality.
These market dynamics are driving process intensification and adoption of disposable technologies and other products that offer convenience, flexibility and the ability to improve capacity utilization in the most modern continuous processing facilities as well as in standard batch processing facilities. The bioprocessing products manufactured by Repligen are designed to address these important needs of biopharmaceutical manufacturers in an increasingly competitive environment.
Kerry is a company rich in heritage. It was during our modest beginnings as a dairy cooperative in Ireland that we developed our unwavering commitment to producing real and wholesome ingredients. Today, we have become a world leader in taste and nutrition for the food and beverage industry.As we’ve evolved over the last 40 years and grown to meet ever-changing consumer demands and expectations, we have remained steadfastly committed to this early ethos. Over the past four decades, our focus on changing lifestyles, the globalisation of food tastes and ever-evolving consumer needs has brought us to a market leading global position with operations in 130 sites across six continents.Our relentless drive to innovate and develop new products to meet the changing needs of our customers has led us to create a network of Global Technology & Innovation Centres and Regional Development & Applications Centres. These centres house more than 900 highly skilled food scientists and nutritionists, and teams of market researchers who provide insights to drive product development. The centres provide unique leading-edge solutions at an unrivalled speed to market, helping to shape the future of food.We are Kerry. Leading to Better in the
Visit their website here https://www.koreabio.org/eng/eng_sub.do?pageNo=01
KoreaBio hopes to vitalize the activities of their individual businesses to gain greater international competitiveness so that they can contribute to further national economic development.
As the organization representing the biotechnology industry as per Article 38 of the Industry Development Act of the Korean Ministry of Trade, Industry & Energy, the Korea Biotechnology Industry Organization strives to enhance links between the many businesses that constitute the biotechnology industry and while acting as a catalyst for further technological development and industrialization.
Japan Bioindustry Association (JBA) is a non-profit organization established in 1987. The organization is planning for sound development in bioscience-related industries and is dedicated to solving problems on a global scale through advances in bioscience. JBA is contributing to society in various areas from the development of advanced technology to the development of industry. Japanese bioindustries have developed with a base in the traditional fermentation industry. However in recent years advances in biotechnology have been made in various fields and this in turn has had an impact on numerous corporations.
JBA’s membership base spans a wide array of corporations that use applications of biotechnology in areas ranging from pharmaceutical and medical supplies, food and cosmetics, as well as chemicals, information, machinery, construction and energy and natural resources. In addition, JBA counts public organizations, universities, public research institutes and a variety of individuals as members. Hence JBA is a unique organization able to comprehensively promote the advancement of bioindustries through the cooperation of industry, academia and government.
Visit the website here https://biopharma-asia.com/
BioPharma Asia aims to keep its readers abreast of all developments in the areas of Drug Development, Drug Delivery, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality articles, written by the most respected authors, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.
Visit their website at www.pharmachinaonline.com
Pharma China is the most trusted English media and business intelligence service covering the Chinese pharmaceutical/biopharmaceutical industry and market.
Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies.
Pharma China Journal Edition (monthly in PDF and Print)
Pharma China Web Edition (continuously-updated news, in-depth commentaries and online databases)
China Pharmaceutical Guide (the most comprehensive and authoritative reference for China’s healthcare sector)
Visit their website at https://www.asiaresearchnews.com/
Asia Research News connects research with the wider world. The service came about in the early 2000s when I heard from several prominent journalists that information about research in Asia was difficult to come by. Being an Asian researcher, and having worked as a journalist, the comments planted a seed that would germinate into Asia Research News.